Skip to main content

Interim report H1 2026

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Strong first half year at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% and the adjusted EBITDA margin expected at the higher end of the 37-38% range. Inaugural share buy-back program announced.

Ester Baiget, President & CEO: “We continue to deliver strong results with positive momentum across all sales areas and in both developed and emerging markets, also driving strong profitability and cash flow. Our sustained performance quarter after quarter underlines the growing need for biosolutions, the strength of our offering and the resilience of our broad market reach. On this basis, we raise the full-year outlook”.

  • Strong broad-based organic sales growth of 8% (Q2: 9%) including ~1.5 pp negative effect from exiting certain countries. Price contributed close to 2 pp and revenue synergies contributed a good 1 pp.
  • Food & Health Biosolutions grew 9% (Q2: 9%) organically driven by Food & Beverages and included ~3 pp negative effect from exiting certain countries; Planetary Health Biosolutions grew 7% (Q2: 9%) organically with both Household Care and Agriculture, Energy & Tech performing very well.
  • Developed markets grew 8% (Q2: 8%) organically and emerging markets 8% (Q2: 11%) including ~4 pp negative effect from exiting certain countries.
  • Adjusted EBITDA margin at 37.7% (Q2: 37.6%), 30bps (Q2: 120bps) higher than last year incl. currency headwind.
  • Adjusted net profit excl. PPA increased 8% (Q2: 9%).
  • NIBD/EBITDA at 1.8x, and free cash flow bef. acq. at 14% of sales. CAPEX-to-sales ratio at 9.7% as planned.
  • 2026 outlook: Organic sales growth range increased to 7-8% (previously 5-7%). Full year outlook includes a close to 1 pp negative effect from exiting certain countries. Adj. EBITDA margin expected at the higher end of the 37-38% range.
  • Interim dividend for first six months of 2026 approved by Board of Directors at DKK 2.35 (EUR 0.31) per share.
  • Inaugural multi-year share buyback program in a total amount of EUR 1 billion approved to be initiated during the second half of 2026 and expected to be completed by the end of 2029.
  • As communicated on August 10, an agreement was signed to acquire the remaining 77% of MicroBioGen.

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.